Amylyx Pharmaceuticals' ALS drug Relyvrio fails to show significant benefits in Phase 3 clinical trial Phoenix.
Amylyx Pharmaceuticals' ALS drug Relyvrio has failed to show significant benefits in a large phase 3 clinical trial, called Phoenix, and may be withdrawn from the market. The drug did not outperform a placebo in improving participants' ALS functional scale, patient-reported quality of life, overall survival, and respiratory function. Amylyx plans to discuss the results with regulatory authorities and the ALS community.
March 08, 2024
16 Articles